17.46 0.93 (5.63%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 20.74 | 1-year : | 24.22 |
Resists | First : | 17.76 | Second : | 20.74 |
Pivot price | 14.84 | |||
Supports | First : | 14.51 | Second : | 12.5 |
MAs | MA(5) : | 15.69 | MA(20) : | 15 |
MA(100) : | 11.67 | MA(250) : | 17.1 | |
MACD | MACD : | 0.6 | Signal : | 0.4 |
%K %D | K(14,3) : | 87.2 | D(3) : | 65.2 |
RSI | RSI(14): 70.9 | |||
52-week | High : | 41.45 | Low : | 8.07 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ENTA ] has closed It is unclear right now based on current values. 85.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 17.79 - 17.86 | 17.86 - 17.93 |
Low: | 16.33 - 16.4 | 16.4 - 16.48 |
Close: | 17.34 - 17.47 | 17.47 - 17.6 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Fri, 29 Mar 2024
Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $19.33 - Defense World
Tue, 26 Mar 2024
Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.33 - MarketBeat
Tue, 26 Mar 2024
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Hold” by Brokerages - Defense World
Tue, 19 Mar 2024
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Position Boosted by Walleye Capital LLC - MarketBeat
Tue, 19 Mar 2024
Should You Hold Enanta Pharmaceuticals Inc (ENTA) Stock Tuesday? - InvestorsObserver
Wed, 06 Mar 2024
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 21 (M) |
Shares Float | 14 (M) |
Held by Insiders | 6 (%) |
Held by Institutions | 100.5 (%) |
Shares Short | 2,090 (K) |
Shares Short P.Month | 1,840 (K) |
EPS | -6.58 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 9.06 |
Profit Margin | -187.8 % |
Operating Margin | -193.8 % |
Return on Assets (ttm) | -22.9 % |
Return on Equity (ttm) | -56.2 % |
Qtrly Rev. Growth | -23.8 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 3.47 |
EBITDA (p.s.) | -6.6 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -93 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -2.66 |
PEG Ratio | 0 |
Price to Book value | 1.92 |
Price to Sales | 5.01 |
Price to Cash Flow | -4 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |